TerminatedPhase 4

Treatment of Giardia Lamblia Infections in Children

Stopped: Extremely slow enrollment

Finland8 participantsStarted 2016-12-01

Plain-language summary

This study investigates the efficacy and safety of rectally administered metronidazole for pediatric Giardia lamblia infection, as well as the acceptance of this treatment regimen by patients/caregivers. The investigators hypothesize that rectal metronidazole is non-inferior to single-dose of oral tinidazole and will cure at least 72% of patients, a well as will be tolerated as good as tinidazole.

Who can participate

Age range6 Months – 10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinical symptoms could be explained by giardiasis AND * fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory (HUSLAB) Exclusion Criteria: * age \<6 mo or \>10 years * weight \<9.5 kg * the absence of symptoms * co-infection with another pathogen, which may cause giardiasis-like symptoms

What they're measuring

Clinical Recovery

Timeframe: 10 days

Trial details

NCT IDNCT02942485

SponsorHelsinki University Central Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

Results submitted2020-09-09

View on ClinicalTrials.gov More GIARDIASIS trials